杭州浙大迪迅生物基因工程有限公司Release date：2020-04-30
Allergy
[IF:6.048]
The first year of treatment predicts the prognosis of asthma over 25 y—A prospective studyDOI: 10.1111/all.13983
Abstract:
Background: An investigator‐driven, real‐life follow‐up study of adult‐onset steroid‐na?ve, newly diagnosed asthma (162 patients) to investigate the treatment results over the 25‐year course of the disease and whether the first treatment year's forced expiratory volume in one second (FEV1) predicts the long‐term prognosis.
Methods: Eighty‐three per cent of the 133 living patients participated in the 25‐year examinations. At this visit, basic asthma examinations including lung function, as well as questionnaires for health‐related quality of life (HRQoL), GINA and the Asthma Control Test, were used for evaluation. The use of medication and remission was verified.
Results: There was no statistically significant change in mean FEV1% predicted (FEV1%) from baseline to the 25‐year control. The changes in FEV1% during the first year predicted the results at the end of follow‐up. Normal FEV1% at the end of the first year predicted normal FEV1, and below‐normal FEV1% at 1 year predicted below‐normal FEV 1% at 25 years. Twenty‐nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS periodically. Clinical remission was reached by 16.4% of the patients, and 7.6% reached functional remission. The general HRQoL remained unchanged.
Conclusion: In adult‐onset asthma, the level of FEV1 reached during the first treatment year seems to predict the later lung function level. One quarter of the patients discontinued the asthma treatment, but their HRQoL was better than that of those continuing to use ICS. Clinical remission was reached by 16% of the patients, which is in concordance with other studies.
First Author:
Ritva Kauppinen
Correspondence:
Jouni Hedman, Department of Pulmonary Diseases, Valto K?kel?nkatu 1, 53130 Lappeenranta, Finland
All Authors:
Ritva Kauppinen, Vesa Vilkka, Harri Sintonen, Jouni Hedman
2020-01-18 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP備14005341號 （浙）-非經(jīng)營性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.haosf.js.cn
COPYRIGHT©2003-2024 www.haosf.js.cn CORPORATION. ALL RIGHTS RESERVED
Official WeChat